|
gptkbp:instanceOf
|
gptkb:drug
antidepressant
|
|
gptkbp:approvedBy
|
1994
|
|
gptkbp:ATCCode
|
N06AX06
|
|
gptkbp:blackBoxWarning
|
liver failure
|
|
gptkbp:brand
|
gptkb:Dutonin
gptkb:Serzone
Nefadar
|
|
gptkbp:CASNumber
|
83366-66-9
|
|
gptkbp:contraindication
|
gptkb:liver_disease
concurrent use with certain CYP3A4 inhibitors
|
|
gptkbp:developedBy
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:eliminationHalfLife
|
2-4 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C25H32ClN5O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nefazodone
|
|
gptkbp:KEGGID
|
D08206
|
|
gptkbp:legalStatus
|
prescription only (in some countries)
withdrawn in several countries
|
|
gptkbp:mechanismOfAction
|
norepinephrine reuptake inhibitor
5-HT2A receptor antagonist
serotonin antagonist and reuptake inhibitor
|
|
gptkbp:MedlinePlusID
|
a697009
|
|
gptkbp:metabolism
|
gptkb:mCPP
gptkb:hydroxynefazodone
liver (CYP3A4, CYP2D6, CYP1A2)
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
99%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1423
4436
4282
DB01149
|
|
gptkbp:regulates
|
approved (US, 1994); withdrawn (2004, US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
drowsiness
liver toxicity
dry mouth
|
|
gptkbp:synonym
|
gptkb:Nefazodone_hydrochloride
|
|
gptkbp:UNII
|
I5Y540LHVR
|
|
gptkbp:usedFor
|
gptkb:major_depressive_disorder
|
|
gptkbp:withdrawn
|
gptkb:Australia
gptkb:Canada
gptkb:Europe
gptkb:New_Zealand
|
|
gptkbp:bfsParent
|
gptkb:Antidepressants
|
|
gptkbp:bfsLayer
|
6
|